^
Association details:
| Biomarker: | EGFR L858R + EGFR L718Q |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
Published date:
10/31/2022
Excerpt:
...we demonstrated the first use of combination therapy with afatinib and cetuximab for a patient with an L858R/L718Q mutation who achieved a response after almonertinib resistance.
DOI:
https://doi.org/10.3389/fonc.2022.995624
